HMG-CoA reductase inhibitors - A review of the recent patent literature

IDrugs

Volumn 5, Issue 3, 2002, Pages 266-277

  Bagi, Cedo M ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [N (2,2,5,5 TETRAMETHYL 1,3 DIOXANE 4 CARBONYL)AMINO]PROPIONIC ACID 2 (3 NEOPENTYL 3 NONYLUREIDO)CYCLOHEXYL ESTER; 3,5 DIHYDROXYHEPTA 6 NOIC ACID DERIVATIVE; 3,5 DIHYDROXYHEPTANOIC ACID DERIVATIVE; ANTILIPEMIC AGENT; ANTIOXIDANT; ANTIVIRUS AGENT; ATORVASTATIN; BAZEDOXIFENE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CERIVASTATIN; CHOLESTEROL; ESTROGEN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; MEVALONIC ACID; MEVINOLIN; PHOSPHODIESTERASE INHIBITOR; PIPENDOXIFENE; PRAVASTATIN; PREDNISONE; PROPRANOLOL; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIMIDYLDIHYDROXYHEPTENOIC ACID DERIVATIVE; RAPAMYCIN; ROSUVASTATIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL;

AGING; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; COLON CANCER; CONTROLLED DRUG RELEASE; DISORDERS OF CHOLESTEROL METABOLISM; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG INDICATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG PURIFICATION; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG WITHDRAWAL; ENDOCYTOSIS; FERMENTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; LIVER METASTASIS; MEDICAL LITERATURE; MICTURITION DISORDER; NONHUMAN; OBESITY; OSTEOARTHRITIS; PATENT; PLEIOTROPY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SKIN DISEASE; TABLET FORMULATION;

EID: 0141449244     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Knopp RH: Drug treatment of lipid disorders. New Engl J Med (1999) 341:498-511. A comprehensive review of the history and perspectives for the use of statins to treat lipid disorders.
2. Davignon J: Methods and endpoints issues in clinical development of lipid-acting agents with pleiotropic effects. Am J Cardiol (1998) 81(Suppl 1):17F-24F. A comprehensive review discussing and exemplifying pleiotropic effects of statins and issues involved in their clinical development. Described pleiotropism provides a basis for the broad claims regarding clinical usage of statins.
3. Mark L, Katona A: Effect of fluvastatin on QT dispersion: A new pleiotropic effect? Am J Cardiol (2000) 85(7):919-920.
4. Wheeler DC: Are there potential non-lipid lowering uses of statins? Drugs (1998) 56(4):517-522.
5. Brown MS, Goldstein JL: Sterol regulatory element binding proteins (SREBPs): Controllers of lipid synthesis and cellular uptake. Nutr Rev (1998) 56:S1-S3.
6. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA (1998) 95(15):8880-8885.
7. Laufs U, Liao J: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 273(37):24266-24271.
8. Garber AJ: Attenuating cardiovascular risk factors in patients with type 2 diabetes. Am Family Physician (2000) 62 (12):2633-2646.
9. Hall A: Rho GTPases and their actin cytoskeleton. Science (1998) 279(5350):509-514.
10. Jick H, Zomberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet (2000) 356(9242):1627-1631.
11. Einhorn TA: Biomechanics of bone. In: Principles of Bone Biology (1996) Bilezikian JP, Raisz LG, Rodan GA (Eds), Academic Press, San Diego, pp 25-37.
12. Mundy GR: Statins and their potential for osteoporosis. Bone (2001) 29(6):495-497. Results demonstrating the pleiotropic effects of statins on the skeleton and exemplifying the use of statins for osteoporosis, based on preclinical data and moderate clinical evidence.
13. AstraZeneca plc (Hill SJ, Lenz EM, Phillips PJ): (E)-7(4-fluorophenyl)-6-isopropyl-2-mesylaminopyridin-5-yl)-(3R,5S)-dihydroxyhep t-6-enoic acid. WO-00185702 (2001).
14. Bristol-Myers Squibb Co (Robl JA, Chen B-C, Sun C-Q): HMG-CoA reductase inhibitors and method. WO-00196311 (2001).
15. Bristol-Myers Squibb Co (Robl JA, Chen B-C, Sun C-Q): HMG-CoA reductase inhibitors and method. WO-00196347 (2001).
16. Andrx Corp (Friedhoff L, Buxbaum J): Method of treating amyloid beta precursor disorders. WO-00132161 (2000).
17. Bayer AG (Bagi CM): Methods of ameliorating abnormal bone states. WO-00137876 (2000).
18. Cellegy Pharmaceuticals Inc (Parks TP, Grayson S): Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism. WO-00178706 (2001).
19. Howard J Smith & Associates Pty Ltd (Smith HJ): Liver-selective therapy. WO-00132162 (2000).
20. St Louis University (Partridge NC): Methods of modulating matrix metalloproteinase activity and uses thereof. WO-00110437 (2000).
21. St Louis University (Partridge NC): Method of modulating expression of LDL-receptor-related protein and uses thereof. WO-00203985 (2001).
22. Université Catholique De Louvain (Balligand J-L, Feron O): Use of compound or pharmaceutical composition for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour development and for wound healing. WO-00111038 (2000).
23. American Home Products Corp (Azrolan NI, Sehgal SN, Adelman SJ): Method of treating cardiovascular disease. WO-00197809 (2001).
24. American Home Products Corp (Jenkins SN, Komm BS, Miller CP): Combinations of statins, estrogenic agents and optionally estrogens. WO-00203977 (2001).
25. Asahi Kasei Corp (Ogawa K, Umeno H): Novel remedies with the use of beta 3 agonist. WO-00154728 (2001).
26. AstraZeneca plc (Bondjers G, Wiklund O, Wikstrand J): New combination of a betablocker and a cholesterol-lowering agent. WO-00174394 (2001).
27. Bayer AG (Bischoff E, Bischoff H, Giuliano F): Novel combination for treatment of sexual dysfunction. WO-00119357 (2000).
28. Bayer AG (Wagener G, Ippen J): Combination of cerivastatin with ACE inhibitors and the use thereof in medicaments. WO-00189525 (2001).
29. Bayer AG (Wagener G, Ziegler R, Lammens RF): Medicament combinations. WO-00121158 (2000).
30. Bayer AG (Bischoff H, Bauersachs J, Ertl G, Fraccarollo D): Use of CSE inhibitors for treating heart failure. WO-00178747 (2001).
31. Hisamitsu Pharmaceutical Co Inc (Tanida N, Goto T, Tomizawa N): Medicinal compositions for treating colorectal cancer. WO-00102014 (2000).
32. Kaneka Corp (Fujii K, Kawabe T, Hosoe K, Hidaka T): Method and compositions for inhibiting arteriosclerosis. WO-00185155 (2001).
33. Merck & Co Inc (Chao Y-S): Anti-hypercholesterolemic drug combination. WO-00122962 (2000).
34. Merck & Co Inc (Waldstreicher J): Combination therapy for treating neurodegenerative disease. WO-00145698 (2000).
35. Merck Frosst Canada & Co (Leblanc Y, Dufresne C, Gauthier JY, Lau CK, Li CS, Roy P, Therien M, Scheigetz J, Wang Z): Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B). WO-00146206 (2000).
36. Merck Frosst Canada & Co (Li CS, Lau CK, Therien M, Gauthier JY, Bayly C, Dufresne C, Fortin R, Leblanc Y, Roy P, et al): Sulfur-substituted aryldifluoromethylphosphonic acids as PTP-1b inhibitors. WO-00170753 (2001).
37. Merck Frosst Canada & Co (Bayly C, Ohkubo M): Sulfur-substituted aryldifluoromethylphosphonic acids as PTP-1b inhibitors. WO-00170754 (2001).
38. Novartis AG (De Gasparo M, Graves KC): Combination of organic compounds. WO-00176573 (2001).
39. Pfizer Products Inc (Day WW, Lee AG, Thompson DD): Compositions and methods for treating osteoporosis. EP-01127573 (2001).
40. Pharmacia Corp (Keller BT, Tremont SJ, Glenn KC, Manning RE): Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders. WO-00168096 (2001).
41. Takeda Chemical Industries Ltd (Sugiyama Y, Odaka H, Naruo K-I): Drug comprising combination. WO-00158491 (2001).
42. Takeda Chemical Industries Ltd (Sugiyama Y, Odaka H, Naruo K, Funatsu M, Ikeya K, Suzuki Y): TNF-α inhibitors. WO-00158443 (2001).
43. Tularik Inc (Li L, Medina JC, Shan B): LXR modulators. WO-00160818 (2000).
44. Andrx Corp (Chen C-M, Chou J, Wong D): HMG-CoA reductase inhibitor extended release formulation. WO-00134123 (2000).
45. AstraZeneca plc (Creekmore JR, Wiggins NA): Pharmaceutical compositions comprising a HMG reductase inhibitor. WO-00154668 (2000).
46. AstraZeneca plc (Creekmore JR, Wiggins NA): Pharmaceutical compositions comprising a HMG CoA reductase inhibitor. WO-00154669 (2000).
47. AstraZeneca PLC (Taylor NP, Okada T): Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] -(3R,5S)-3,5-dihydroxyhept-6-enoic acid. WO-00160804 (2001).
48. Biocon India Ltd (Sambasivam G, Sridharan M, Acharya P, Mathew J): Process for manufacturing simvastatin and the novel intermediates. WO-00134590 (1999).
49. Biocon India Ltd (Sambasivan G, Sridharan M, Padudevastana S, Poornaprajna A, Matthew J, Srinath S, Nair S): Synthesis of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methyle thyl)-3-phenyl-4-[(phenylamino)carbonyl)]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin). WO-00172706 (2000).
50. Biological Gyogyszergyar RT (Keri V, Deak L, Forgacs I, Szabo C, Nagyne EA): Process for recovering statin compounds from a fermentation broth. WO-00139768 (2000).
51. Cheil Je Dang Corp (Lee KH, Kim JW, Choi KD, Bae H): A process for producing simvastatin. WO-00172734 (2000).
52. Ciba Specialty Chemicals Holding Inc (Wolleb A, Wolleb H): Process for the preparation of indole derivatives and intermediates of the process. WO-00192223 (2001).
53. Gyogyszerkutato Intezet KFT (Jekkel A, Ambrus G, Ilkoy E, Horvath I, Konya A, Szabo IM, Nagy Z, Horvath G, Mozes J et al): Hydroxylation of compactin to pravastatin by micromonospora. WO-00104340 (2000).
54. Lek Pharmaceutical and Chemical Co DD (Pflaum Z, Kere J): Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same. WO-00193860 (2000).
55. Lek Pharmaceuticl and Chemical Co DD (Pflaum Z, Milivojevic D, Rucman B, Kogej S): Stable pharmaceutical product and formulation. WO-00193859 (2000).
56. Lek Pharmaceutical and Chemical Co DD (Pflaum Z): Crystals of the sodium salt of pravastatin. WO-00110813 (2000).
57. Lek Pharmaceutical and Chemical Co DD (Pflaum Z): Process for the preparation of amorphous atorvastatin. WO-00142209 (2000).
58. Merck & Co Inc (McManus J, Anousis N, Genus J, Hancock C): Lactonization process. WO-00130773 (2000).
59. Nichiiko Pharmaceutical Co Ltd (Okabe M): Method of production flavastatin. JP-13286293 (2000).
60. Nissan Chemical Industries Ltd (Matsumoto H, Horiuchi T): Process for producing 2-aminobenzophenone compound. US-06310249 (1999).
61. Nissan Chemical Industries Ltd (Ohara Y, Suzuki M, Yanagawa Y, Takada Y): Process for the preparation of quinoline derivative and intermediate therefor. US-06335449 (1999).
62. NitroSystems Inc (Miller RA): A therapeutic mixture of HMG-CoA reductase inhibitors. WO-00128499 (2000). Example of claims where the combination of two different classes of statins could be used to achieve synergism in a known disease area, or to expand the claims to 'new' disease areas based on pleiotropic properties of one or both statins used in combination.
63. Novartis AG (Kalb OM, Valazza SJ): Organic compounds. US-06242003 (2000).
64. Ranbaxy Laboratories Ltd (Narula P, Raman S, Kumar ML, Kumar P): Process for the preparation of sodium salts of statins. WO-00144144 (2000).
65. Ranbaxy Laboratories Ltd (Kumar P, Raman S, Narula P): Process for the isolation of lovastatin. WO-00200615 (2001).
66. Teva Pharmaceutical Industries Ltd (Ayalon A, Levinger M, Roytblat S, Niddam V, Lifshitz R): Polymorphic form of atorvastatin calcium. WO-00136384 (2000).
67. Teva Pharmaceuticals USA Inc (Keri V, Forgas I): A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities. WO-00166538 (2001).
68. Warnere Lambert R&D Ireland Ltd (Tully W): A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt. WO-00144180 (2000).
69. Warner Lambert R&D Ireland Ltd (Connell J, Tully W, Madigan E): A process for producing crystalline atorvastatin calcium. WO-00144181 (2000).